Pulmonary hemosiderosis in children with bronchopulmonary dysplasia

David Kurahara1, Marina Morie1, Maya Yamane1

  • 1Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.

Insights

This study suggests a link between pulmonary hemosiderosis (PH) and bronchopulmonary dysplasia (BPD) in premature infants. Mycophenolate mofetil (MMF) showed promise in treating PH, warranting further investigation.

Area of Science:

  • Pediatrics
  • Pulmonology
  • Neonatology

Background:

  • Bronchopulmonary dysplasia (BPD) is a chronic lung disease common in premature infants.
  • Pulmonary hemosiderosis (PH) is characterized by iron deposition in the lungs.
  • A potential association between BPD and PH has not been extensively studied.

Purpose of the Study:

  • To explore a possible association between bronchopulmonary dysplasia (BPD) and pulmonary hemosiderosis (PH).
  • To report on two cases of PH in infants with a history of BPD.
  • To review existing literature on the BPD-PH association and treatment options.

Main Methods:

  • Case report of two patients with PH and a history of BPD.
  • Bronchoalveolar lavage to identify hemosiderin-laden macrophages.
  • Literature review on the association between PH and BPD.

Main Results:

  • Both patients presented with symptoms of PH and had a history of prematurity and BPD.
  • Intravenous corticosteroids led to rapid improvement in pulmonary infiltrates.
  • Mycophenolate mofetil (MMF) facilitated mechanical ventilation weaning in one patient.

Conclusions:

  • A possible correlation exists between prematurity-associated BPD and PH.
  • MMF may be a life-saving treatment for PH, similar to its use in systemic lupus erythematosus-related pulmonary hemorrhage.
  • Further research is needed to confirm the PH-BPD association and evaluate MMF efficacy in PH treatment.

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
23
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
4.6K
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet...
21
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
19
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
16
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.7K